Cite
HARVARD Citation
Porter, R. et al. (n.d.). TP015/#1566 A phase 2, two-stage, study of mirvetuximab soravtansine (IMGN853) in combination with pembrolizumab in patients with microsatellite stable (MSS) recurrent or persistent endometrial cancer (EC). International journal of gynecological cancer. pp. A229-A230. [Online].